Dr. Bendell on FDA Approval of Regorafenib in Liver Cancer

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the FDA approval of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the FDA approval of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

Related Content:

Sarah Cannon Research InstituteOncLive TVGastrointestinal Cancer
Combination Regimens Make Their Mark in Frontline HCC
Dr Bishop on 34-Month Data With Anitocabtagene Autoleucel in R/R Myeloma
Dr Leslie on the 5-Year Follow-Up of the ZUMA-5 Trial in R/R Indolent NHL